Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saxagliptin + dapagliflozin versus each agent alone as add-on to metformin in inadequately controlled type 2 diabetes (Phase III)
2015-005406-11Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Saxagliptin + dapagliflozin add-on to metformin, Saxagliptin add-on to metformin and Dapagliflozin add-on to metformin (3 arms). Primary endpoint: Change from baseline HbA1c to week 24. Started Feb 2016; status: completed.
02
Drugs
saxagliptindapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2015-005406-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005406-11.